Literature DB >> 7489622

Accelerated thrombolysis with high dose bolus t-PA extends the role of peripheral thrombolysis but may increase the risks.

B D Braithwaite1, P A Birch, K R Poskitt, B P Heather, J J Earnshaw.   

Abstract

Low dose intra-arterial thrombolysis is too slow for many patients with severe acute limb ischaemia. Accelerated thrombolysis with high dose bolus t-PA was used in a consecutive series of 43 patients. Complete or clinically useful lysis was achieved in 39 patients, with a median duration of 7 h. Lysis occurred in 46% in under 4 h. Fifty-six per cent of patients required further procedures after lysis. Eleven per cent suffered a major bleed. The limb salvage rate at 30 days was 56%. Amputation was required in 22% and 22% died. Most deaths were due to associated thrombotic conditions: myocardial infarction (5), pulmonary embolism (1) and malignant thrombosis (1). One patient died from pneumonia two weeks after lysis and two died from renal failure within a week of thrombolysis. The high mortality rate was not associated with bleeding but may reflect the high risks involved in treating this group of patients. High dose bolus t-PA infusion appears to predict immediate outcome of thrombolysis as well as reducing infusion times. It may expand the indications for the non-surgical treatment of acute limb ischaemia to include most patients with the condition. Careful case selection is still necessary for optimal results.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489622     DOI: 10.1016/s0009-9260(05)83212-x

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Effects of Intravenous and Catheter Directed Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator (Alteplase) in Non-Traumatic Acute Limb Ischemia; A Randomized Double-Blind Clinical Trial.

Authors:  Abbas Saroukhani; Hassan Ravari; Masoud Pezeshki Rad
Journal:  Bull Emerg Trauma       Date:  2015-07

2.  Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion.

Authors:  O Grip; M Kuoppala; S Acosta; A Wanhainen; J Åkeson; M Björck
Journal:  Br J Surg       Date:  2014-06-25       Impact factor: 6.939

3.  Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial.

Authors:  Chen Wang; Zhenguo Zhai; Yuanhua Yang; Qi Wu; Zhaozhong Cheng; Lirong Liang; Huaping Dai; Kewu Huang; Weixuan Lu; Zhonghe Zhang; Xiansheng Cheng; Ying H Shen
Journal:  Chest       Date:  2009-09-09       Impact factor: 9.410

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.